Boehringer Ingelheim’s business development team has scorched out of the traps in 2024. On Thursday, Jan. 4, the German drugmaker unveiled its second deal of the year, revealing another T-cell anticancer therapy partnership with 3T Biosciences to swell the potential payday to $538.5 million.One year ago, Boehringer struck a deal to feed its patient-derived T-cell […]
